and myxofibrosarcoma (MFS), and has rights in the US, Canada, and Mexico. Alphamab and 3D Med, meanwhile, are running a phase 3 study in patients with advanced biliary tract cancer (BTC ...
Last year, biotech shutdowns spiked. Thankfully, 2024’s numbers are a little lower, dropping from the 27 closures in 2023 to 22 this year.
NE Bartlett et al (2021) 59 Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases Pembrolizumab + limb infusion of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback